GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen

Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes

(2015)   DIABETES CARE

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015

(2015) Yehuda Handelsman et al.   Endocrine Practice

Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice

(2015) Carla Francés Artigas et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

(2015) Caroline M. Apovian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

(2015) Lawrence Blonde et al.   LANCET

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

(2015) Annachiara Uccellatore et al.   Diabetes Therapy

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

(2015) Annachiara Uccellatore et al.   Diabetes Therapy

Glycemic Variability: How Do We Measure It and Why Is It Important?

(2015) Sunghwan Suh et al.   Diabetes & Metabolism Journal

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial

(2014) W. Lane et al.   DIABETES OBESITY & METABOLISM

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

(2014) Conrad Eng et al.   LANCET

Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus

(2013) Catherine Sheffield et al.   Endocrine Practice

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs

(2012) Morgan Bron et al.   POSTGRADUATE MEDICINE

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

(2011) D. Russell-Jones et al.   DIABETES CARE

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis

(2011) A. E. Pontiroli et al.   DIABETES OBESITY & METABOLISM

The Effect of Liraglutide Added to U-500 Insulin in Patients with Type 2 Diabetes and High Insulin Requirements

(2011) Wendy Lane et al.   Diabetes Technology & Therapeutics

Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus

(2010) Maria Tzefos et al.   ANNALS OF PHARMACOTHERAPY

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

(2010) A. Garber et al.   DIABETES OBESITY & METABOLISM

Exenatide therapy in insulin-treated type 2 diabetes and obesity

(2010) U. A. Nayak et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

(2009) Nancy M. Yoon et al.   CLINICAL THERAPEUTICS

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET